Pexidartinib Hydrochloride and Protonix oral/injection
Determining the interaction of Pexidartinib Hydrochloride and Protonix oral/injection and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with proton pump inhibitors (PPIs) may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown. MANAGEMENT: Concomitant use of pexidartinib with proton pump inhibitors should be avoided. If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist. References "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Professional:GENERALLY AVOID: Coadministration with proton pump inhibitors (PPIs) may significantly decrease the bioavailability and therapeutic effects of pexidartinib. The proposed mechanism is a pH-dependent reduction in drug dissolution and/or absorption. Concomitant administration of esomeprazole, a proton pump inhibitor, decreased pexidartinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 55% and 50%, respectively. The effect of coadministration with an H2-receptor antagonist or locally-acting antacids on pexidartinib pharmacokinetics is unknown.
MANAGEMENT: Concomitant use of pexidartinib with proton pump inhibitors should be avoided. If acid-suppression therapy is required, pexidartinib may be administered 2 hours before or 2 hours after taking a locally-acting antacid, or if using an H2-receptor antagonist, administer pexidartinib at least 2 hours before or 10 hours after taking the H2-receptor antagonist.
- "Product Information. Turalio (pexidartinib)." Daiichi Sankyo, Inc., Parsippany, NJ.
Generic Name: pexidartinib
Brand name: Turalio
Synonyms: Pexidartinib
Generic Name: pantoprazole
Brand name: Protonix, Protonix IV
Synonyms: Protonix
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Pexidartinib Hydrochloride-Protonix Tablets
- Pexidartinib Hydrochloride-Protopam
- Pexidartinib Hydrochloride-Protopam Chloride
- Pexidartinib Hydrochloride-Protophylline Alcohol And Sugar Free
- Pexidartinib Hydrochloride-Protriptyline
- Pexidartinib Hydrochloride-Protriptyline Hydrochloride
- Protonix oral/injection-Pfizerpen
- Protonix oral/injection-Pharaon Tea
- Protonix oral/injection-Pharmorubicin Pfs
- Protonix oral/injection-Phazyme
- Protonix oral/injection-Phazyme Liquid Gas Relief, Maximum Strength
- Protonix oral/injection-Phena-Plus